Fc Receptor (FcR) Inhibitor

Fc Receptor (FcR) Inhibitors (27):

Cat. No.	Nombre del producto	Efecto	Pureza

HY-147305

Efgartigimod alfa	Inhibitor	99.47%
Efgartigimod alfa (ARGX-113) is a reversibility, humanized ^Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.

HY-P99009

Batoclimab	Inhibitor	99.89%
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.

HY-P991922

AKIR001	Inhibitor
AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [¹⁷⁷Lu] radiolabeled AKIR001, namely [¹⁷⁷Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma.

HY-P99125

Anti-Mouse CD16/CD32 Antibody (2.4G2)	Inhibitor
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.

HY-P99300

Ligelizumab	Inhibitor	99.85%
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).

HY-N0762

Isobavachin	Inhibitor	99.88%
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.

HY-P990863

Anti-CD32/FcγRIIA Antibody (IV.3)	Inhibitor
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody inhibitor, targeting to human CD32/FcγRIIA. Anti-CD32/FcγRIIA Antibody (IV.3) can block Fc receptor IIA. Anti-CD32/FcγRIIA Antibody (IV.3) can be used for the researches of inflammation and infection, such as arthritis and E. coli infection.

HY-P990676

VIB-9600	Inhibitor	99.41%
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990291

Anti-Mouse CD16.2 Antibody (9E9)	Inhibitor
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation.

HY-P991086

MGD010	Inhibitor	99.06%
MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases.

HY-P991705

Nebaprubart	Inhibitor
Nebaprubart (JJP-1212) is a humanized IgG4κ antibody against FCAR/CD89, and its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

HY-182476

Z223-2027	Inhibitor
Z223-2027 is a FcRn inhibitor. Z223-2027 competitively blocks the binding of immunoglobulin G (IgG) to FcRn. Z223-2027 can be used in the research of IgG-mediated autoimmune diseases.

HY-P990818

Anti-Rat FcRn heavy chain heterodimers Antibody (1G3)	Inhibitor
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is an anti-rat FcRn heavy chain heterodimers IgG1 monoclonal antibody. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can effectively bind to FcRn and competitively inhibit the binding of IgG to FcRn. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can reduce the total serum IgG level. Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) can be used for researches on autoimmune conditions such as experimental autoimmune myasthenia gravis (EAMG). The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P991074

GMA-161	Inhibitor
GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990413

Anti-Fc gamma R1 Antibody	Inhibitor
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-182943

BTK-IN-49	Inhibitor
BTK-IN-49 is a selective, orally active and brain-penetrant BTK inhibitor with an IC₅₀ of 0.14 nM. BTK-IN-49 binds to BTK and blocks B-cell receptor and Fcγ receptor signaling. BTK-IN-49 inhibits the proliferation of CNS-compartmentalized B-cells and FcγR-induced microglial proliferation in a BTK-dependent manner. BTK-IN-49 can be used for the study of multiple sclerosis.

HY-145775

hIgG-hFc receptor-IN-1	Inhibitor
hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC₅₀ of 2 μM .

HY-158316

BTL-MK	Inhibitor
BTL-MK (Compound 19) an orally active antiallergic agent, that inhibits degranulation of mast cells with an IC₅₀ of 6.7 μM, through binding to the inhibitory receptor FcγRIIB. BTL-MK improves the metaboilic stability in human liver microsomes. BTL-MK ameliorates the allergic response in Ovalbumin, low endotoxin (HY-W250978A)-induced food allergy mice model. BTL-MK exhibits a good pharmacokinetic character with metabolic stability.

HY-P991998

Anti-Human/Monkey CD16a Antibody (3G8)	Inhibitor
Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology.

HY-N11725

Phlorofucofuroeckol A	Inhibitor
Phlorofucofuroeckol A is a FcεRI inhibitor with low cytotoxicity toward basophilic leukemia cells. Phlorofucofuroeckol A suppresses binding activity between IgE and FcεRI receptor. Phlorofucofuroeckol A inhibits histamine release from basophilic leukemia cells stimulated by IgE/anti-IgE or calcium ionophore A23187 (HY-N6687). Phlorofucofuroeckol A inhibits β-hexosaminidase release from basophilic leukemia cells stimulated by IgE/DNP-BSA. Phlorofucofuroeckol A can be used for the research of allergy disease.

Name
E-mail *

	Sorry, but the email address you supplied was invalid.